Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB6103
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Parenteral
01
Overview
EB6103 is a small molecule glycomacrolide being developed by EmpathBio for the treatment of leukemia and solid tumors. It functions by targeting the F subunit of ATP synthase/hydrolase, an enzyme complex critical for cellular energy production and metabolic regulation. By modulating this target, EB6103 aims to selectively disrupt the bioenergetics of malignant cells, which frequently exhibit metabolic vulnerabilities compared to healthy cells. The program is currently in the IND-enabling phase of development.
02
Targets
ATP5PF (ATP synthase subunit F6, mitochondrial)
Beyond the preview
Go deeper on EB6103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB6103.